Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

European Journal of Pharmacology

Volumn 390, Issue 3, 2000, Pages 245-248

  Bymaster, Frank P ^a   Falcone, Julie F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Binding; Clozapine; Muscarinic receptor; Olanzapine

Indexed keywords

ATROPINE; CLOZAPINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; OLANZAPINE; RECEPTOR SUBTYPE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CHO CELL; CONTROLLED STUDY; CYTOLYSIS; DRUG RECEPTOR BINDING; HUMAN; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BENZODIAZEPINES; BINDING, COMPETITIVE; CHO CELLS; CLOZAPINE; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOTONIC SOLUTIONS; ISOTONIC SOLUTIONS; MEMBRANES; N-METHYLSCOPOLAMINE; PIRENZEPINE; RADIOLIGAND ASSAY; RECEPTORS, MUSCARINIC; TRITIUM;

EID: 0034598980     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00037-6     Document Type: Article

References (15)

1. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
2. Beasley C.M., Tollefson G.D., Tran P., Satterlee W., Sanger T., Holman S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
3. Birdsall N.J.M., Burgen A.S.V., Hulme E.C., Wells J.W. The effect of ions on the binding of agonists and antagonists to muscarinic receptors. Br. J. Pharmacol. 67:1979;371-377.
4. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
5. 1-adrenergic receptors in vitro. Schizophr. Res. 37:1999;107-122.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3090-3108.
7. De Lean A., Munson P., Rodbard D. Simultaneous analysis of families of sigmoidal cures: application to bioassay, radioligand assay and physiological dose-response curves. Am. J. Physiol. 235:1978;E97-E102.
8. Dorje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M.R. Antagonist binding profiles of five cloned muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256:1991;727-733.
9. Moore N.A., Leander J.D., Benvenga M.J., Gleason S.D., Shannon H. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J. Clin. Psychiatry. 58(suppl 10):1997;37-44.
10. Olianas M.C., Maulla C., Onali P. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology. 20:1999;263-270.
11. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
12. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Curr. Opin. Neurol. Neurosurg. 6:1993;602-608.
13. Zeng X.P., Le F., Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. 321:1997;349-354.
14. 2A and muscarinic receptors. Psychopharmacology. 141:1999;267-278.
15. Zorn S.H., Jones S.B., Ward K.M., Liston D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur. J. Pharmacol., Mol. Pharmacol. Sect. 269:1994;R1-R2.